A structured consultation framework for healthcare professionals evaluating pacing-induced cardiomyopathy, conduction system pacing candidacy, and Aveir VR device performance.
When a patient with a leadless pacemaker develops evidence of pacing-induced cardiomyopathy (PICM) — declining ejection fraction, high right ventricular pacing burden, and chronically elevated biomarkers — the consultation with a specialist electrophysiologist becomes one of the most consequential clinical encounters in their care.
This article presents 15 structured, evidence-informed questions organized into four clinical domains: PICM assessment thresholds, LBBAP upgrade candidacy and procedural planning, Aveir VR device-specific management, and broad strategic decision-making. These questions are intended to facilitate a high-yield consultation with a specialist experienced in conduction system pacing.
The clinical scenario guiding these questions: a patient with complete heart block, an Aveir VR leadless pacemaker (implanted May 2024), 97% RV pacing burden, ejection fraction declining to 45–50%, and persistently elevated hs-TnT since implant — consulting an expert in LBBAP at a high-volume center.
What ejection fraction threshold and RV pacing burden percentage do you use before formally recommending upgrade evaluation?
There is no universally agreed cutoff. Most published series use EF below 50% with burden above 20–40%, but with near-total burden from implant, the evaluation timeline may be accelerated regardless of absolute EF.
Threshold criteriaHow long do you observe EF decline before recommending LBBAP upgrade — and does the observation window shorten when pacing burden is near 100% from the start?
In acquired complete heart block with permanent ventricular pacing dependence, there is no "low-burden phase." The dyssynchrony is continuous from day one, potentially shortening the defensible observation window.
TimelineDo you incorporate chronically elevated high-sensitivity troponin T (hs-TnT) into the upgrade decision, or do you rely primarily on serial imaging?
Persistently elevated hs-TnT in the setting of high-burden RV pacing and EF decline may reflect ongoing myocardial injury beyond what echocardiography captures. Although not in current formal PICM criteria, some centers treat it as a supporting biomarker for earlier intervention.
Biomarker strategyBeyond echocardiography, do you use cardiac MRI, CT, or strain imaging to stage PICM — including fibrosis burden and LV dyssynchrony index?
CMR-based late gadolinium enhancement may identify fibrotic remodeling that predicts a less robust EF response to upgrade. Global longitudinal strain by echo can quantify dyssynchrony independent of EF and may refine the upgrade indication.
Advanced imagingWhat lead and delivery system do you prefer for LBBAP? Do you use the SelectSecure 3830 exclusively, or do you have experience with alternative conduction system pacing leads?
The SelectSecure 3830 remains the most widely used lead for LBBAP, though newer dedicated CSP leads are entering the market. The operator's volume and preferred approach directly affect procedural success rates and fluoroscopy time.
Lead selectionWhat complications should I anticipate when co-implanting a transvenous LBBAP lead alongside an existing Aveir VR leadless pacemaker?
Specific considerations include subclavian or cephalic access in the context of a device already occupying the RV, potential for RV sensing interference between systems, and the need to confirm that the LBBAP lead does not interact with the Aveir VR tine anchoring mechanism.
Procedural riskPost-upgrade, would you retain the Aveir VR as a backup pacemaker (reprogrammed to VVI at low rate), or do you recommend retrieval?
Retention simplifies the procedure and preserves a backup in case LBBAP capture is lost. Retrieval eliminates device interaction risk but adds procedural complexity, particularly at longer implant durations where fibrous encapsulation may have progressed.
Device co-managementWhat is your institutional LBBAP volume, and do you have local outcome data on conduction system capture confirmation rates, fluoroscopy time, and lead revision rates?
Operator and center volume is the single strongest predictor of procedural success in LBBAP. Published high-volume series report CSP capture in over 90% of attempts, but rates vary widely by operator experience.
Institutional volumeAt 97% pacing burden and typical programming, what realistic battery longevity does the Aveir VR offer — and how does output amplitude affect that projection?
Abbott's labeling and postmarket data suggest 8–13 years of battery life for the Aveir VR under nominal conditions, but near-100% burden significantly compresses this estimate. Real-world data specific to pacing-dependent patients with complete heart block are limited.
Battery longevityHow do you counsel patients with the Aveir VR on intermittent non-capture alerts — particularly nocturnal events — and when should such alerts prompt emergent evaluation?
The Aveir VR's adaptive threshold testing algorithm runs periodic pacing threshold measurements that can trigger non-capture events. In pacing-dependent patients with complete heart block, distinguishing algorithm-driven non-capture from true threshold elevation is critical for patient education and triage.
Safety counselingIs there published data on Aveir VR retrieval rates and procedural risk at 18–24 months post-implant, if LBBAP upgrade makes retrieval the preferred strategy?
The Aveir retrieval system was designed for extraction up to 6 weeks post-implant under ideal conditions, though retrieval at later timepoints has been reported. Risk increases with implant duration due to fibrotic integration.
Retrieval dataDo you initiate guideline-directed medical therapy (GDMT) — such as sacubitril/valsartan or beta-blocker titration — first and reassess in 3–6 months, or does a 97% pacing burden make early upgrade the dominant strategy regardless of EF response to medication?
GDMT and LBBAP upgrade are not mutually exclusive, but the sequence matters. In pacing-dependent patients where the primary driver of LV dysfunction is mechanical dyssynchrony rather than neurohormonal activation, the GDMT-first approach may simply delay the inevitable correction of the underlying problem.
Treatment sequencingIf LBBAP capture cannot be confirmed intraoperatively, what is your fallback — His bundle pacing, biventricular pacing, or abandoning the CSP approach?
Procedural failure of LBBAP is uncommon at experienced centers but not zero. Pre-procedure discussion of the contingency plan — particularly in a pacing-dependent patient where any procedural complication carries elevated risk — is essential informed consent and clinical planning.
Contingency planningPost-upgrade, what is your echocardiographic follow-up protocol — and at what timepoint and EF recovery threshold do you consider the intervention a success?
Most published LBBAP upgrade series report peak EF recovery at 3–6 months. Understanding the center's success definition and follow-up protocol allows the patient to set appropriate expectations and monitor their own trajectory.
Post-procedure monitoringPhysician to physician — given EF 45–50%, 97% pacing burden, and persistently elevated hs-TnT since implant in May 2024, would you upgrade me now or continue observing?
This question, framed explicitly as a collegial peer-to-peer exchange after rapport is established, often unlocks the most clinically useful answer. Specialist electrophysiologists frequently give more nuanced guidance when the patient is also a fellow physician who can receive — and needs — a fully unvarnished assessment.
The frank question — ask this lastThere is no single universally accepted threshold. Most published definitions of PICM require an EF below 50% with high-burden RV pacing (typically defined as ≥20–40%) in the absence of another explanation for LV dysfunction. However, when pacing burden approaches 100% from the time of implant — as in pacing-dependent complete heart block — many electrophysiologists apply a lower threshold for initiating upgrade evaluation, particularly if there is corroborating evidence such as elevated biomarkers or echocardiographic signs of dyssynchrony.
Yes, co-habitation of the Aveir VR with a subsequently implanted transvenous LBBAP lead is technically feasible and has been described in clinical practice. The Aveir VR would typically be reprogrammed to a backup VVI pacing mode at a low rate to minimize interaction with the dominant LBBAP system. Retrieval remains an option but carries procedural risk that increases with implant duration due to progressive fibrous tissue integration around the tines.
High-sensitivity troponin T elevation in the context of high-burden RV pacing and EF decline suggests ongoing myocardial injury that may exceed what standard imaging reveals. While hs-TnT is not yet incorporated into formal PICM diagnostic criteria or guideline recommendations for upgrade timing, a growing body of literature supports its use as a biomarker of cardiomyocyte stress in device patients. Many experienced electrophysiologists factor persistently elevated hs-TnT into the overall clinical picture when weighing the urgency of upgrade, particularly when other criteria are borderline.
Both His bundle pacing (HBP) and left bundle branch area pacing (LBBAP) are forms of conduction system pacing (CSP) that aim to restore physiologic ventricular activation by engaging the native conduction system. HBP targets the bundle of His at the AV node level, achieving very narrow paced QRS morphology but carrying higher risks of threshold instability and sensing issues over time. LBBAP engages the left bundle branch or its fascicular divisions more distally by driving a helix-tipped lead through the interventricular septum, offering more stable thresholds and higher capture rates at the cost of a slightly wider paced QRS. Most high-volume operators now favor LBBAP for PICM upgrade due to superior long-term lead performance.
Pacing-dependent patients — particularly those with complete heart block and no reliable underlying escape rhythm — should have a low threshold for emergent evaluation with any sustained non-capture event. Symptomatic non-capture (presyncope, syncope, extreme fatigue, dyspnea at rest) warrants immediate evaluation regardless of cause. Asymptomatic device-triggered threshold testing events (a feature of the Aveir VR algorithm) should be distinguished from true capture loss through patient education and, ideally, through remote monitoring follow-up with the managing electrophysiology team.